cinoxacin
Trade name: cinobac
Small moleculeapproved
Approved
Jun 13, 1980
Cinoxacin is a synthetic antibacterial agent for oral administration. Cinoxacin mode of action involves the inhibiting of DNA gyrase, a type II topoisomerase, and topoisomerase IV. Adverse effects are nausea, anorexia, vomiting, abdominal cramps/pain, perverse taste, diarrhea, headache, dizziness, rash, urticaria, pruritus, edema and other. — NCATS
Clinical trial activity
0 trials · 0 clinical orgs · 2 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
0
Timeline
Indications
Approved for
Mechanism of action
- Bacterial DNA gyraseINHIBITOR
Bacterial DNA gyrase inhibitor
Approval history
- approvedJun 13, 1980
Chemistry & pharmacology
Loading structure…
SMILES
CCN1N=C(C(O)=O)C(=O)C2=C1C=C3OCOC3=C2- Mol. weight
- 262.2182 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
- Availability
- Discontinued
Oral
Yes
Parenteral
No
Topical
No
Sources
- WikipediaCinoxacin ↗
- NCATSLMK22VUH23 ↗
- ChEMBLCHEMBL1208 ↗
- ChEMBLCHEMBL151676 ↗
- ChEMBLCHEMBL1200446 ↗
- ChEMBLCHEMBL1200769 ↗
- ChEMBLCHEMBL1241 ↗
Also known as
- 1-ethyl-6,7-methylenedioxy-4(1h)-oxocinnoline-3-carboxylic acid
- 1-ethyl-6,7-methylenedioxy-4(1h)-oxocinnoline-3-carboxylic acid
- 5-ethyl-8-oxo-5,8-dihydro-1,3-dioxa-5,6-diaza-cyclopenta[b]naphthalene-7-carboxylic acid
- 5-ethyl-8-oxo-5,8-dihydro-1,3-dioxa-5,6-diaza-cyclopenta[b]naphthalene-7-carboxylic acid
- 64716
- cinobac
- cinobac
- cinobac
- cinobac
- cinobactin
- cinoxacin
- cinoxacin
- cinoxacin
- cinoxacin
- cinoxacin
- cinoxacin
- cinoxacin
- cinoxacin
- cinoxacin
- cinoxacin
- cinoxacin
- cinoxacine
- cinoxacine
- cinoxacino
- cinoxacino
- cinoxacinum
- cinoxacinum